Expert Interview
A Fifth Take: Looking at Momelotinib & Pacritinib in treating Myelofibrosis
Ticker(s): SRRA, CTICInstitution: Mount Sinai
- Assistant Professor at the Mount Sinai Health System (Icahn School of Medicine).
- Manages 40-50 patients with MF currently and is familiar with the MOMENTUM trial.
- Research interests include myeloproliferative neoplasms, especially polycythemia vera and myelofibrosis, as well as acute myeloid leukemia, hemophagocytic lymphohistiocytosis, systemic mastocytosis, and chronic myelomonocytic leukemia and has published extensively on these topics.
Please describe your clinical practice and research relating to MF.
Added By: joe_mccannOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Momelotinib? on Pacritinib?
Added By: joe_mccannWhat do you expect the Danazol arm to do on A) TSS B) TI C) SVR?
What do you expect the Momelotinib arm to do on A) TSS B) TI C) SVR?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
